Skip to main content

Advertisement

Table 3 Baseline and ongoing data collection

From: Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study

Baseline data and follow-up data at month 6, 12 and 24
MRI kidney volumetry
Creatinine clearance and estimated GFR (Cockcroft-Gault)
Proteinuria (24-hour urine and spot urine)
Physical examination and vital signs
Laboratory tests
   Haematology/Biochemistry
   Lipid profile
   Sirolimus trough level
Pregnancy test1
Serological testing for hepatitis B, C and human immunodeficiency virus (HIV)1
MEMS® check
Adverse events and concomitant therapy
Follow-up data every 3 months
Serum creatinine
Proteinuria (spot urine)
Physical examination and vital signs
Laboratory tests
   Haematology/Biochemistry
Lipid profile
   Sirolimus trough level
Adverse events and concomitant therapy
  1. 1Only at baseline and month 24